These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23354833)

  • 21. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
    Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
    Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
    J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
    Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
    J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
    Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
    J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
    Kaloshi G; Brace G; Rroji A; Bushati T; Roci E; Hoxha M; Fejzo G; Petrela M
    Tumori; 2013; 99(5):601-3. PubMed ID: 24362864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC; Colman H; Kim BT; Raizer J
    J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
    Chan DT; Poon WS; Chan YL; Ng HK
    Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rechallenge with temozolomide in patients with recurrent gliomas.
    Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
    J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide or bevacizumab for spinal cord high-grade gliomas.
    Kaley TJ; Mondesire-Crump I; Gavrilovic IT
    J Neurooncol; 2012 Sep; 109(2):385-9. PubMed ID: 22678696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
    Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
    J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
    Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A
    Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.